MBRX - Moleculin Biotech Inc logo

MBRX

Moleculin Biotech Inc

Rev โ€”top 1%10Y
Hold

Moleculin Biotech develops therapeutic candidates targeting tumors and viruses. Its key products include Annamycin for acute myeloid leukemia and a portfolio of immune modulators and glycolysis inhibitors aimed at brain and pancreatic cancers.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth9.62%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-90.84%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-5x
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend10%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-5x
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev Trend10%
Revenue Consistency

See the full market ranking โ†’

Moleculin Biotech Inc fundamental performance

Across Moleculin Biotech Inc's full reported history, from 2016 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 3M to -$ 33M. Revenue increased in 10% of the years measured; net income in 30%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.52โ€”
1 Year2025-08-12
$ 16.55-96.85%
5 Years2021-08-12
$ 1.1K-99.95%
10 Years2016-08-12
$ 14.11K-100.00%
All Time2016-06-02
$ 18K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 30M$ 10M
2025$ 0.00-$ 33M$ 8M
2024$ 0.00-$ 21M$ 4M
2023$ 0.00-$ 29M$ 23M
2022$ 0.00-$ 29M$ 43M
2021$ 0.00-$ 15M$ 70M
2020$ 0.00-$ 17M$ 15M
2019$ 0.00-$ 13M$ 10M
2018$ 0.00-$ 11M$ 7M
2017$ 9K-$ 9M$ 7M
IPO2016$ 0.00-$ 3M$ 5M

Explore beyond MBRX

You're looking at Moleculin Biotech Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies